Michigan Adult Vaccine Program (MI-AVP)

Only the vaccines listed below are provided for uninsured and underinsured adults 19 years of age or older, who meet certain risk factors and are seen at LHDs, FQHCs, Migrant Health Centers (MHCs) and Tribal Health Centers (THCs). Rural Health Centers (RHCs) and private providers cannot participate in this program. Adults with vaccine insurance coverage or Medicaid do not qualify for this program, however, adults with a Medicaid spend down are considered uninsured and would be eligible until their spend-down is met. Medicaid will cover vaccine and administration costs for the vaccines included in the MI-AVP Program. LHDs, FQHCs, MHCs and THCs must use privately purchased vaccine for adult Medicaid-enrolled clients and bill Medicaid.

Tdap or Td

Tdap is recommended to be given to all persons aged 19 years and older:
- If they have no documentation of a previous dose of Tdap
  - Regardless of the interval since their last Td dose (when pertussis protection is needed, there is no minimal interval between the last dose of Td and a dose of Tdap)
  - Even if they are not in contact with infants less than 12 months of age
- Tdap is recommended during each pregnancy (preferably during 27 to 36 weeks of gestation)

Persons aged 19 and older should receive a Td booster every 10 years once they have received one dose of Tdap.

MMR

Adults born on or after 1/1/57, who do not have a documented history of having received one or more doses of MMR vaccine at least 28 days apart. An adult that previously had only one dose of MMR and qualifies for MI-VRP may receive the second dose of MMR under this program.

Hepatitis A

Persons who meet one of the following criteria:
- Household and/or sexual contact of a hepatitis A virus (HAV)-infected person
- Men who have sex with men (MSM)
- Acute or chronic liver disease, including those with hepatitis B virus (HBV) and/or hepatitis C virus (HCV)
- Use of injection or non-injection illegal drugs
- Have blood clotting disorders
- Traveling to or working in countries where HAV is endemic
- Unvaccinated persons who anticipate close personal contact (e.g., household or regular babysitting) with an international adoptee during the first 60 days after arrival in the United States from an endemic country

Hepatitis B

Persons who meet one of the following criteria:
- A household and/or sexual contact of a hepatitis B surface antigen (HBsAg)-
positive person

- Sexually active person who is not in a long-term mutually monogamous relationship (e.g., a person with more than one sex partner during the previous 6 months)
- Person seeking evaluation or treatment for a sexually transmitted disease
- Men who have sex with men (MSM)
- Current or recent illegal injection-drug user
- Person with end-stage renal disease, including predialysis, hemodialysis, peritoneal dialysis, or home dialysis
- Person with acute or chronic liver disease, including those with hepatitis C virus (HCV)
- Person with diabetes
- Person with HIV infection
- Persons seeking treatment at: STD treatment facilities, HIV testing and treatment facilities, facilities providing drug abuse treatment and prevention services, health care settings targeting services to injection drug users or men who have sex with men, correctional facilities, end-stage renal disease programs and facilities for chronic hemodialysis patients, and institutions and nonresidential day care facilities for persons with developmental disabilities
- International travelers to regions with intermediate or high levels (HBsAg prevalence of ≥2%) of endemic HBV infection; visit www.cdc.gov/travel/default.aspx, for countries with intermediate or high levels of HBV infection
- Persons susceptible to HBV infection who are foreign-born from HBV endemic countries (for a list of these countries, visit CDC’s website at http://wwwnc.cdc.gov/travel/yellowbook/2016/infectious-diseases-related-to-travel/hepatitis-b.

Pre- and/or post-vaccination serology may be considered for at-risk adults. For more information, please refer to:

HPV

Individuals who meet one of the following criteria:

- Females age 19 years through 26 years, without history of completed series
- Males age 19 years through 21 years, without history of completed series
- Males age 22 through 26 years, within a high risk group
  - Immunocompromised due to infection (including HIV), disease or medication
  - Men having sex with men
    - Including those who identify as gay, bisexual or transgender

PCV13

Individuals 19 years and older with one of the following criteria:

- Have CSF leak
- Cochlear implant
- Functional or anatomic asplenia (including sickle cell disease or splenectomy)
• Immunocompromising conditions including: HIV infection, leukemia, lymphoma, Hodgkin’s disease, multiple myeloma, generalized malignancy, chronic renal failure or nephrotic syndromes, congenital or acquired immunodeficiencies
• Receiving treatment using immunosuppressive drugs, including long-term corticosteroids or radiation therapy
• Received a solid organ transplant
• 65 years and older who have never received one dose of PCV13, give one dose


PPSV23
Persons who meet the following criteria:
• 19 through 64 years with asthma or who smoke cigarettes
• Chronic lung, liver or heart disease, diabetes mellitus, alcoholism, CSF leaks, or cochlear implants
• Functional or anatomic asplenia (including sickle cell disease or splenectomy)
• Immunocompromising conditions including: HIV infection, leukemia, lymphoma, Hodgkin’s disease, multiple myeloma, generalized malignancy, chronic renal failure or nephrotic syndromes, congenital or acquired immunodeficiencies
• Receiving treatment using immunosuppressive drugs, including long-term corticosteroids or radiation therapy
• Received a solid organ transplant
• 65 years and older—if never received a dose at or after 65 years give one dose


Zoster
Adults age 60 years and older, regardless of zoster disease history, who have no insurance coverage for this vaccine (a high co-pay does not make them eligible for the vaccine).

An adult with a complete documented series of a vaccine is considered up to date and not eligible for MI-AVP. The administration fee for MI-AVP vaccines should not exceed $23.03. If the administration fee poses a barrier to receiving the vaccine, please consider waiving the fee.